SCHEMBL1024697

SCHEMBL1024697

O=C(Cl)Oc1ccc(Cl)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.43
DAO P14920 1/20 0.43
GSK3B P49841 1/20 0.39
TSHR P16473 1/20 0.35
ALDH1A1 P00352 7/20 0.35
HPGD P15428 3/20 0.35
PPARA Q07869 1/20 0.34
KDM4E B2RXH2 3/20 0.33
GAA P10253 2/20 0.33
POLB P06746 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
KMT2A Q03164 2/20 0.33
HTT P42858 2/20 0.33
RAB9A P51151 1/20 0.33
GABBR2 O75899 1/20 0.33
GABBR1 Q9UBS5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8672684 0.86 ALDH1A1 (0.32) F2DAOALDH1A1
SCHEMBL486042 0.83 DAO (0.48) F2DAOGSK3BTSHRALDH1A1
SCHEMBL7003234 0.81 F2 (0.42) F2DAOGSK3BTSHRALDH1A1
SCHEMBL8189892 0.78 POLB (0.40) F2DAOGSK3BTSHRALDH1A1
SCHEMBL4769604 0.77 DAO (0.42) DAOALDH1A1HPGDKDM4EGAA
SCHEMBL9817948 0.77 CES2 (0.43) DAOGSK3BALDH1A1HPGDKDM4E
SCHEMBL25246892 0.76 F2 (0.38) F2DAOGSK3BTSHRALDH1A1
SCHEMBL4070283 0.69 KMT2A (0.47) F2DAOGSK3BALDH1A1HPGD
SCHEMBL13624441 0.68 GSK3B (0.39) F2DAOGSK3BALDH1A1HPGD
SCHEMBL9218012 0.68 DAO (0.45) DAOGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099453-B1 Combination therapy of substituted oxazolidinones BAYER IP GMBH (DE) 2017-09-06 EP disclosed
EP-1526132-B1 Substituted oxazolidinone derivatives and their use as factor xa inhibitors BAYER IP GMBH (DE) 2014-03-12 EP disclosed
EP-1928867-B1 2-AMINOETHOXYACETIC ACID DERIVATIVES AND THEIR USE IN TREATING THROMBOEMBOLIC DISORDERS BAYER IP GMBH (DE) 2013-05-22 EP disclosed
EP-2132193-B1 SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS BOEHRINGER INGELHEIM INT (DE) 2012-10-24 EP disclosed
EP-2388260-A1 Method for producing a blood coagulation factor inhibitor Archimica GmbH (DE) 2011-11-23 EP disclosed
EP-1899330-B9 SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT BOEHRINGER INGELHEIM INT (DE) 2011-11-09 EP disclosed
US-8038533-B2 Game system using parent game machine and child game machine NINTENDO CO., LTD. (JP) 2011-10-18 US disclosed
EP-1945634-B1 PHENYLENEBISOXAZOLIDINE DERIVATIVES AND THEIR USE AS ANTICOAGULANTS BAYER SCHERING PHARMA AG (DE) 2011-01-19 EP disclosed
EP-1899330-B1 SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT BOEHRINGER INGELHEIM INT (DE) 2010-11-24 EP disclosed
EP-1874764-B1 IMINO-OXAZOLIDINES AND USE THEREOF AS ANTICOAGULANTS BAYER SCHERING PHARMA AG (DE) 2010-11-10 EP disclosed
WO-2003007942-A1 SUBSTITUTED ISOINDOLES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2003-01-30 WO disclosed
WO-2003000256-A1 SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY BAYER HEALTHCARE AG (DE) 2003-01-03 WO disclosed
WO-2001047919-A9 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION BAYER AG (DE) 2002-12-19 WO disclosed
EP-1261606-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION Bayer Aktiengesellschaft (DE) 2002-12-04 EP disclosed
EP-1252163-A2 4-PYRIDYL-AND 2,4-PYRIMIDINYL-SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE IN PHARMACY MERCKLE GMBH (DE) 2002-10-30 EP disclosed
WO-2001057042-A2 4-PYRIDYL-AND 2,4-PYRIMIDINYL-SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE IN PHARMACY MERCKLE GMBH (DE) 2001-08-09 WO disclosed
WO-2001047919-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION BAYER AKTIENGESELLSCHAFT (DE) 2001-07-05 WO disclosed
EP-0109381-B1 THIOPHENE-2-CARBOXYLIC-ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION Laevosan-Gesellschaft m.b.H. (AT) 1986-07-30 EP disclosed
EP-0126225-A1 Process for the preparation of substituted trialkylsilyloxymalonic-acid dinitriles BAYER AG (DE) 1984-11-28 EP disclosed
EP-0109381-A1 Thiophene-2-carboxylic-acid derivatives and process for their preparation Laevosan-Gesellschaft m.b.H. (AT) 1984-05-23 EP disclosed